---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000043"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-07-13T13:03:54+00:00"
generated_at: "2026-07-13T13:05:06.254537+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified

## Summary
- Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.
- Approximately half of planned clinical sites for REO 033 Part A activated by end of July; more than 20 patients pre-identified.
- Initial tumor response update from Part A expected by year-end 2026; Part B enrollment could begin Q1 2027 subject to FDA feedback.
- Pelareorep has Fast Track designation from FDA for RAS-mutant MSS metastatic colorectal cancer.
- Global lead PI Dr. Sanjay Goel opened enrollment at Rutgers Cancer Institute; remaining sites to be activated by end of August.

## SEC filing metadata
- accession: 0001129928-26-000043
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-07-13T13:03:54+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000043/0001129928-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000043/oncy-20260713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000043
- JSON: https://secwatch.observer/filing/0001129928-26-000043.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.